Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
T WalterCEPD investigators

Abstract

Diagnosis and management of poorly differentiated gastro-entero-pancreatic (GEP) neuroendocrine carcinomas (NECs) remain challenging. Recent studies suggest prognostic heterogeneity. We designed within the French Group of Endocrine Tumours a prospective cohort to gain insight in the prognostic stratification and treatment of GEP-NEC. All patients with a diagnosis of GEP-NEC between 1st January 2010 and 31st December 2013 could be included in this national cohort. Adenoneuroendocrine tumours were excluded. 253 patients from 49 centres were included. Median age was 66 years. Main primary locations were pancreas (21%), colorectal (27%), oesophagus-stomach (18%); primary location was unknown in 20%. Tumours were metastatic at diagnosis in 78% of cases. Performance status (PS) at diagnosis was 0-1 in 79% of patients. Among the 147 (58%) cases reviewed by an expert pathological network, 39% were classified as small cell NEC and 61% as large cell NEC. Median Ki67 index was 75% (range, 20-100). Median overall survival was 15.6 (13.6-17.0) months. Significant adverse prognostic factors in univariate analysis were PS > 1 (hazard ratio [HR] = 2.5), metastatic disease (HR = 1.6), NSE>2 upper limit of normal [ULN]; HR = 3.2), CgA>2 ULN (HR ...Continue Reading

Citations

Dec 13, 2018·Endocrine-related Cancer·Esben Andreas CarlsenHalfdan Sorbye
Sep 29, 2020·World Journal of Gastroenterology : WJG·Rani KanthanSelliah C Kanthan
Apr 14, 2020·Pancreas·Patrick W McGarrahThorvardur R Halfdanarson
Oct 30, 2019·World Journal of Gastroenterology : WJG·Melissa FrizzieroMairéad G McNamara
Jun 5, 2020·Journal of Clinical Medicine·Anna Pellat, Romain Coriat
Apr 13, 2021·Reviews in Endocrine & Metabolic Disorders·Paula Espinosa-OlarteRocio Garcia-Carbonero
Jun 11, 2021·Current Treatment Options in Oncology·Kazhan MollazadeganJoakim Crona
May 18, 2021·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Julien HadouxRomain Desgrippes
Jul 12, 2021·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Akihiro OhmotoShunji Takahashi
Aug 4, 2021·Journal of Neuroendocrinology·Jain PranteshAmr Mohamed
Aug 8, 2021·Cancers·Anna PellatRomain Coriat
Sep 9, 2021·Clinical Journal of Gastroenterology·Taro KogamiWasaburo Koizumi
Oct 23, 2019·Neuroendocrinology·Julien HadouxEric Baudin

❮ Previous
Next ❯

Related Concepts

Related Feeds

CZI Human Cell Atlas Seed Network

The aim of the Human Cell Atlas (HCA) is to build reference maps of all human cells in order to enhance our understanding of health and disease. The Seed Networks for the HCA project aims to bring together collaborators with different areas of expertise in order to facilitate the development of the HCA. Find the latest research from members of the HCA Seed Networks here.

Carcinoma, Islet Cell (Keystone)

Islet Cell Carcinoma or Pancreatic Neuroendocrine Tumours arise in the hormone producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on islet cell carcinoma in this feed.

Carcinoma, Islet Cell

Islet Cell Carcinoma or Pancreatic Neuroendocrine Tumours arises in the hormone producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on Islet Cell Carcinoma here.

Adenoma, Islet Cell

Islet Cell Adenoma arises in the islet cells, which are insulin producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on Islet Cell Adenoma here.

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.